Journal
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
Volume 19, Issue 5, Pages 655-666Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1871520619666181218164050
Keywords
Angiogenesis; canine mammary tumors; hypoxia; hypoxia-inducible factor-1 alpha; mammary tumors; metformin; vascular endothelial growth factor
Categories
Funding
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP [2012/14079-6, 2013/19862-2]
- Fundacao de Apoio a Pesquisa e Extensao de Sao Jose do Rio Preto - FAPERP [091/2014]
Ask authors/readers for more resources
Background: The angiogenesis process is regulated by many factors, such as Hypoxia-Inducible Factor-1 (HIF-1) and Vascular Endothelial Growth Factor (VEGF). Metformin has demonstrated its ability to inhibit cell growth and the LY294002 is the major inhibitor of PI3K/AKT/mTOR pathway that has antiangiogenic properties. Methods: Canine mammary tumor cell lines CMT-U229 and CF41 were treated with metformin and LY294002. Cell viability, protein and gene expression of VEGF and HIF-1 were determined in vitro. For the in vivo study, CF41 cells were inoculated in female athymic nude mice treated with either metformin or LY294002. The microvessel density by immunohistochemistry for CD31 as well as the gene and protein expression of HIF-1 and VEGF were evaluated. Results: The treatment with metformin and LY294002 was able to reduce the cellular viability after 24 hours. The protein and gene expression of HIF-1 and VEGF decreased after treatment with metformin and LY294002. In the in vivo study, there was a decrease in tumor size, protein and gene expression of HIF-1 and VEGFA, in addition to the decreasing of CD31 expression after all treatments. Conclusion: Our results demonstrate the effectiveness of metformin and LY294002 in controlling the angiogenesis process in mammary tumors by VEGF and HIF-1, the most important angiogenic markers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available